{"title":"印度尼西亚接受抗逆转录病毒治疗的艾滋病毒阳性儿童的血脂异常","authors":"Pratama Wicaksana, N. Kurniati, S. Pardede","doi":"10.5114/HIVAR.2021.105086","DOIUrl":null,"url":null,"abstract":"Introduction: Antiretroviral (ARV) therapy has changed the status of human immunodeficiency virus (HIV) infection from a high-mortality disease into a chronic one. One of the consequences of long-term use of ARV medications is dyslipidemia, which may progress to cardiovascular disease in the future. The aim of the study was to measure the rate of dyslipidemia among HIV-infected children receiving ARV therapy and related risk factors. Material and methods: A cross-sectional study was conducted at pediatric outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January to July 2019. Lipid profile was examined on 96 eligible subjects and data regarding nutritional status, clinical stage at diagnosis, latest immunosuppression status, latest viral load (VL) value, and latest ARV combination used were obtained from medical records. Bivariate and multivariate analysis were performed to find the association between dependent and independent variables using SPSS version 22. Results: Of 96 subjects included, 52 (54.2%) subjects experienced dyslipidemia. The prevalence of dyslipidemia among those with second-line (containing protease inhibitors) and first-line (contain-ing non-nucleoside reverse transcriptase inhibitors) ARV therapy were 80% and 39%, respectively. The use of second-line ARV therapy was associated with 6.3 times ( p < 0.01; 95% CI: 2.4-17.1) increased risk of dyslipidemia compared to first-line ARV therapy. Conclusions: Prevalence of dyslipidemia among HIV-positive children on ARV was high with sec-ond-line ARV therapy being a risk factor. children, HIV, dyslipidemia, HAART, protease inhibitors.","PeriodicalId":53943,"journal":{"name":"HIV & AIDS Review","volume":null,"pages":null},"PeriodicalIF":0.3000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Dyslipidemia among HIV-positive children receiving antiretroviral therapy in Indonesia\",\"authors\":\"Pratama Wicaksana, N. Kurniati, S. Pardede\",\"doi\":\"10.5114/HIVAR.2021.105086\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Antiretroviral (ARV) therapy has changed the status of human immunodeficiency virus (HIV) infection from a high-mortality disease into a chronic one. One of the consequences of long-term use of ARV medications is dyslipidemia, which may progress to cardiovascular disease in the future. The aim of the study was to measure the rate of dyslipidemia among HIV-infected children receiving ARV therapy and related risk factors. Material and methods: A cross-sectional study was conducted at pediatric outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January to July 2019. Lipid profile was examined on 96 eligible subjects and data regarding nutritional status, clinical stage at diagnosis, latest immunosuppression status, latest viral load (VL) value, and latest ARV combination used were obtained from medical records. Bivariate and multivariate analysis were performed to find the association between dependent and independent variables using SPSS version 22. Results: Of 96 subjects included, 52 (54.2%) subjects experienced dyslipidemia. The prevalence of dyslipidemia among those with second-line (containing protease inhibitors) and first-line (contain-ing non-nucleoside reverse transcriptase inhibitors) ARV therapy were 80% and 39%, respectively. The use of second-line ARV therapy was associated with 6.3 times ( p < 0.01; 95% CI: 2.4-17.1) increased risk of dyslipidemia compared to first-line ARV therapy. Conclusions: Prevalence of dyslipidemia among HIV-positive children on ARV was high with sec-ond-line ARV therapy being a risk factor. children, HIV, dyslipidemia, HAART, protease inhibitors.\",\"PeriodicalId\":53943,\"journal\":{\"name\":\"HIV & AIDS Review\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.3000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"HIV & AIDS Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5114/HIVAR.2021.105086\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"HIV & AIDS Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5114/HIVAR.2021.105086","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 1
摘要
抗逆转录病毒(ARV)治疗使人类免疫缺陷病毒(HIV)感染从一种高死亡率疾病转变为一种慢性疾病。长期使用抗逆转录病毒药物的后果之一是血脂异常,未来可能发展为心血管疾病。该研究的目的是测量接受抗逆转录病毒治疗的艾滋病毒感染儿童的血脂异常率及其相关危险因素。材料和方法:2019年1月至7月在印度尼西亚雅加达Cipto Mangunkusumo医院儿科门诊进行了一项横断面研究。对96名符合条件的受试者进行血脂检查,并从医疗记录中获取营养状况、诊断时的临床阶段、最新免疫抑制状态、最新病毒载量(VL)值和最新ARV联合使用的数据。使用SPSS version 22进行双变量和多变量分析以发现因变量和自变量之间的关联。结果:纳入的96名受试者中,52名(54.2%)出现了血脂异常。二线(含蛋白酶抑制剂)和一线(含非核苷逆转录酶抑制剂)抗逆转录病毒治疗的血脂异常患病率分别为80%和39%。使用二线抗逆转录病毒治疗与6.3倍相关(p < 0.01;95% CI: 2.4-17.1)与一线抗逆转录病毒治疗相比,血脂异常的风险增加。结论:在接受抗逆转录病毒药物治疗的hiv阳性儿童中,血脂异常的患病率很高,二线抗逆转录病毒药物治疗是一个危险因素。儿童,HIV,血脂异常,HAART,蛋白酶抑制剂。
Dyslipidemia among HIV-positive children receiving antiretroviral therapy in Indonesia
Introduction: Antiretroviral (ARV) therapy has changed the status of human immunodeficiency virus (HIV) infection from a high-mortality disease into a chronic one. One of the consequences of long-term use of ARV medications is dyslipidemia, which may progress to cardiovascular disease in the future. The aim of the study was to measure the rate of dyslipidemia among HIV-infected children receiving ARV therapy and related risk factors. Material and methods: A cross-sectional study was conducted at pediatric outpatient clinic, Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from January to July 2019. Lipid profile was examined on 96 eligible subjects and data regarding nutritional status, clinical stage at diagnosis, latest immunosuppression status, latest viral load (VL) value, and latest ARV combination used were obtained from medical records. Bivariate and multivariate analysis were performed to find the association between dependent and independent variables using SPSS version 22. Results: Of 96 subjects included, 52 (54.2%) subjects experienced dyslipidemia. The prevalence of dyslipidemia among those with second-line (containing protease inhibitors) and first-line (contain-ing non-nucleoside reverse transcriptase inhibitors) ARV therapy were 80% and 39%, respectively. The use of second-line ARV therapy was associated with 6.3 times ( p < 0.01; 95% CI: 2.4-17.1) increased risk of dyslipidemia compared to first-line ARV therapy. Conclusions: Prevalence of dyslipidemia among HIV-positive children on ARV was high with sec-ond-line ARV therapy being a risk factor. children, HIV, dyslipidemia, HAART, protease inhibitors.